T1	tradename 0 9	Krystexxa
T2	nanoparticle 11 23	pegloticase)
T3	tradename 146 155	KRYSTEXXA
T4	tradename 218 238	KRYSTEXXA KRYSTEXXA
T5	nanoparticle 240 252	pegloticase)
T6	routeofadministration 268 279	intravenous
T7	fdaapprovaldate 312 316	2010
T8	adversereaction 327 338	ANAPHYLAXIS
T9	adversereaction 343 361	INFUSION REACTIONS
T10	adversereaction 434 445	Anaphylaxis
T11	adversereaction 450 468	infusion reactions
T12	tradename 533 542	KRYSTEXXA
T13	tradename 564 573	KRYSTEXXA
T14	adversereaction 668 679	anaphylaxis
T15	adversereaction 684 703	infusion reactions.
T16	co-administereddrug 753 767	antihistamines
T17	co-administereddrug 772 788	corticosteroids.
T18	adversereaction 874 885	anaphylaxis
T19	tradename 910 920	KRYSTEXXA.
T20	adversereaction 1233 1244	Anaphylaxis
T21	adversereaction 1287 1304	Infusion Reaction
T22	tradename 1390 1399	KRYSTEXXA
T23	nanoparticle 1401 1413	pegloticase)
T24	surfacecoating 1419 1428	PEGylated
T25	activeingredient 1429 1454	uric acid specific enzyme
T26	indication 1487 1499	chronic gout
T27	tradename 1591 1600	KRYSTEXXA
T28	dose 1769 1773	8 mg
T29	routeofadministration 1786 1797	intravenous
T30	frequency 1807 1824	every two weeks.
T31	routeofadministration 1865 1876	intravenous
T32	routeofadministration 1919 1923	oral
T33	tradename 1963 1972	KRYSTEXXA
T34	co-administereddrug 2097 2111	antihistamines
T35	co-administereddrug 2117 2133	corticosteroids.
T36	adversereaction 2239 2251	anaphylaxis.
T37	tradename 2282 2291	KRYSTEXXA
T38	routeofadministration 2334 2345	intravenous
T39	dose 2568 2572	8 mg
T40	nanoparticle 2577 2588	pegloticase
T41	activeingredient 2611 2618	uricase
T42	tradename 2792 2802	KRYSTEXXA,
T43	adversereaction 3049 3073	Anaphylaxis: Anaphylaxis
T44	tradename 3109 3119	KRYSTEXXA.
T45	adversereaction 3120 3131	Anaphylaxis
T46	adversereaction 3267 3293	hypersensitivity reactions
T47	tradename 3320 3329	KRYSTEXXA
T48	adversereaction 3423 3435	anaphylaxis.
T49	co-administereddrug 3475 3489	antihistamines
T50	co-administereddrug 3494 3510	corticosteroids.
T51	adversereaction 3587 3598	anaphylaxis
T52	tradename 3623 3633	KRYSTEXXA.
T53	adversereaction 3651 3690	Infusion Reactions: Infusion reactions
T54	tradename 3725 3746	KRYSTEXXA. KRYSTEXXA
T55	adversereaction 3841 3860	infusion reactions.
T56	co-administereddrug 3899 3913	antihistamines
T57	co-administereddrug 3918 3934	corticosteroids.
T58	adversereaction 3987 4006	infusion reactions.
T59	adversereaction 4026 4044	infusion reaction,
T60	adversereaction 4228 4245	infusion reaction
T61	adversereaction 4322 4334	Gout Flares:
T62	adversereaction 4350 4361	gout flares
T63	tradename 4457 4467	KRYSTEXXA.
T64	adversereaction 4473 4483	gout flare
T65	tradename 4509 4518	KRYSTEXXA
T66	adversereaction 4545 4555	Gout flare
T67	co-administereddrug 4575 4620	non-steroidal anti-inflammatory drugs [NSAID]
T68	co-administereddrug 4624 4634	colchicine
T69	adversereaction 4791 4816	Congestive Heart Failure:
T70	tradename 4817 4826	KRYSTEXXA
T71	adversereaction 4874 4899	congestive heart failure,
T72	tradename 4992 5001	KRYSTEXXA
T73	adversereaction 5023 5047	congestive heart failure
T74	tradename 5240 5257	KRYSTEXXA-treated
T75	adversereaction 5272 5322	gout flares, infusion reactions, nausea, contusion
T76	adversereaction 5326 5392	ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis
T77	adversereaction 5397 5406	vomiting.
T78	company 5461 5490	Savient Pharmaceuticals, Inc.
T79	tradename 5516 5526	KRYSTEXXA)
T80	adversereaction 5751 5762	ANAPHYLAXIS
T81	adversereaction 5767 5785	INFUSION REACTIONS
T82	adversereaction 5971 5982	Anaphylaxis
T83	adversereaction 5988 6006	Infusion Reactions
T84	adversereaction 6012 6023	Gout Flares
T85	adversereaction 6029 6053	Congestive Heart Failure
T86	tradename 6077 6086	KRYSTEXXA
T87	adversereaction 6689 6700	Anaphylaxis
T88	adversereaction 6705 6723	Infusion Reactions
T89	adversereaction 6790 6801	Gout Flares
T90	adversereaction 7000 7011	ANAPHYLAXIS
T91	adversereaction 7016 7034	INFUSION REACTIONS
T92	adversereaction 7044 7055	Anaphylaxis
T93	adversereaction 7060 7078	infusion reactions
T94	tradename 7143 7153	KRYSTEXXA.
T95	adversereaction 7205 7216	Anaphylaxis
T96	adversereaction 7354 7380	hypersensitivity reactions
T97	tradename 7416 7425	KRYSTEXXA
T98	adversereaction 7519 7530	anaphylaxis
T99	adversereaction 7535 7554	infusion reactions.
T100	co-administereddrug 7602 7616	antihistamines
T101	co-administereddrug 7621 7637	corticosteroids.
T102	adversereaction 7723 7734	anaphylaxis
T103	tradename 7759 7769	KRYSTEXXA.
T104	tradename 7997 8006	KRYSTEXXA
T105	nanoparticle 8008 8020	pegloticase)
T106	surfacecoating 8026 8035	PEGylated
T107	activeingredient 8036 8061	uric acid specific enzyme
T108	indication 8094 8106	chronic gout
T109	tradename 8479 8488	KRYSTEXXA
T110	tradename 8635 8644	KRYSTEXXA
T111	dose 8667 8671	8 mg
T112	activeingredient 8673 8680	uricase
T113	routeofadministration 8702 8713	intravenous
T114	tradename 8777 8786	KRYSTEXXA
T115	tradename 8848 8857	KRYSTEXXA
T116	tradename 9091 9100	KRYSTEXXA
T117	routeofadministration 9321 9332	intravenous
T118	tradename 9494 9503	KRYSTEXXA
T119	tradename 9574 9583	KRYSTEXXA
T120	tradename 9952 9961	KRYSTEXXA
T121	tradename 9990 9999	KRYSTEXXA
T122	routeofadministration 10019 10030	intravenous
T123	routeofadministration 10168 10179	intravenous
T124	tradename 10235 10244	KRYSTEXXA
T125	routeofadministration 10266 10270	oral
T126	routeofadministration 10328 10332	oral
T127	tradename 10378 10387	KRYSTEXXA
T128	adversereaction 10430 10441	anaphylaxis
T129	adversereaction 10446 10464	infusion reactions
T130	tradename 10761 10770	KRYSTEXXA
T131	routeofadministration 10812 10823	intravenous
T132	co-administereddrug 10974 11006	antihistamines, corticosteroids)
T133	adversereaction 11032 11043	anaphylaxis
T134	adversereaction 11048 11067	infusion reactions.
T135	tradename 11079 11088	KRYSTEXXA
T136	adversereaction 11160 11171	anaphylaxis
T137	adversereaction 11176 11195	infusion reactions,
T138	adversereaction 11322 11339	infusion reaction
T139	tradename 11376 11386	KRYSTEXXA,
T140	tradename 11737 11746	KRYSTEXXA
T141	nanoparticle 11798 11809	pegloticase
T142	activeingredient 11861 11868	uricase
T143	tradename 11879 11888	KRYSTEXXA
T144	tradename 11993 12002	KRYSTEXXA
T145	tradename 12324 12334	KRYSTEXXA.
T146	adversereaction 12369 12380	Anaphylaxis
T147	adversereaction 12431 12442	anaphylaxis
T148	tradename 12506 12515	KRYSTEXXA
T149	frequency 12516 12530	every 2 weeks,
T150	adversereaction 12586 12623	wheezing, peri-oral or lingual edema,
T151	adversereaction 12627 12651	hemodynamic instability,
T152	adversereaction 12668 12672	rash
T153	adversereaction 12676 12686	urticaria.
T154	routeofadministration 12761 12765	oral
T155	co-administereddrug 12766 12780	antihistamine,
T156	routeofadministration 12784 12795	intravenous
T157	co-administereddrug 12796 12810	corticosteroid
T158	co-administereddrug 12818 12832	acetaminophen.
T159	adversereaction 12902 12913	anaphylaxis
T160	tradename 13005 13014	KRYSTEXXA
T161	adversereaction 13105 13117	anaphylaxis.
T162	adversereaction 13190 13201	Anaphylaxis
T163	adversereaction 13337 13363	hypersensitivity reactions
T164	adversereaction 13464 13475	anaphylaxis
T165	tradename 13500 13510	KRYSTEXXA.
T166	adversereaction 13634 13645	anaphylaxis
T167	adversereaction 13710 13721	anaphylaxis
T168	routeofadministration 14036 14040	oral
T169	tradename 14068 14077	KRYSTEXXA
T170	tradename 14175 14184	KRYSTEXXA
T171	routeofadministration 14206 14210	oral
T172	routeofadministration 14269 14273	oral
T173	tradename 14309 14319	KRYSTEXXA.
T174	adversereaction 14325 14343	Infusion Reactions
T175	tradename 14458 14467	KRYSTEXXA
T176	dose 14468 14472	8 mg
T177	frequency 14473 14487	every 2 weeks,
T178	tradename 14521 14530	KRYSTEXXA
T179	dose 14531 14535	8 mg
T180	frequency 14536 14550	every 4 weeks,
T181	adversereaction 14606 14624	infusion reactions
T182	routeofadministration 14672 14676	oral
T183	co-administereddrug 14677 14691	antihistamine,
T184	routeofadministration 14692 14703	intravenous
T185	co-administereddrug 14704 14718	corticosteroid
T186	co-administereddrug 14726 14740	acetaminophen.
T187	adversereaction 14810 14828	infusion reactions
T188	tradename 14920 14929	KRYSTEXXA
T189	adversereaction 15020 15039	infusion reactions.
T190	co-administereddrug 15076 15090	antihistamines
T191	co-administereddrug 15095 15111	corticosteroids.
T192	tradename 15112 15121	KRYSTEXXA
T193	adversereaction 15197 15215	infusion reaction,
T194	tradename 15710 15719	KRYSTEXXA
T195	tradename 15817 15826	KRYSTEXXA
T196	tradename 15951 15961	KRYSTEXXA.
T197	adversereaction 15967 15990	Gout Flares Gout flares
T198	tradename 16021 16031	KRYSTEXXA.
T199	adversereaction 16077 16088	gout flares
T200	adversereaction 16255 16265	Gout flare
T201	co-administereddrug 16285 16329	non-steroidal anti-inflammatory drug (NSAID)
T202	co-administereddrug 16333 16343	colchicine
T203	tradename 16405 16414	KRYSTEXXA
T204	tradename 16505 16514	KRYSTEXXA
T205	adversereaction 16704 16728	Congestive Heart Failure
T206	tradename 16729 16738	KRYSTEXXA
T207	adversereaction 16786 16811	congestive heart failure,
T208	tradename 16937 16946	KRYSTEXXA
T209	adversereaction 16968 16992	congestive heart failure
T210	tradename 17065 17074	KRYSTEXXA
T211	tradename 17162 17171	KRYSTEXXA
T212	tradename 17251 17261	KRYSTEXXA,
T213	adversereaction 17322 17333	anaphylaxis
T214	adversereaction 17338 17357	infusion reactions.
T215	adversereaction 17615 17627	anaphylaxis,
T216	tradename 17691 17700	KRYSTEXXA
T217	dose 17701 17705	8 mg
T218	frequency 17706 17720	every 2 weeks,
T219	adversereaction 17752 17771	infusion reactions,
T220	tradename 17834 17843	KRYSTEXXA
T221	dose 17844 17848	8 mg
T222	frequency 17849 17863	every 2 weeks,
T223	adversereaction 17905 17916	gout flares
T224	tradename 17985 17994	KRYSTEXXA
T225	routeofadministration 18100 18104	oral
T226	co-administereddrug 18105 18119	antihistamine,
T227	routeofadministration 18120 18131	intravenous
T228	co-administereddrug 18132 18146	corticosteroid
T229	co-administereddrug 18154 18167	acetaminophen
T230	adversereaction 18179 18190	anaphylaxis
T231	adversereaction 18195 18213	infusion reaction.
T232	co-administereddrug 18237 18274	non-steroidal anti-inflammatory drugs
T233	co-administereddrug 18278 18289	colchicine,
T234	adversereaction 18322 18332	gout flare
T235	tradename 18362 18371	KRYSTEXXA
T236	tradename 18523 18532	KRYSTEXXA
T237	indication 18550 18562	chronic gout
T238	tradename 18760 18769	KRYSTEXXA
T239	dose 18770 18774	8 mg
T240	tradename 18820 18829	KRYSTEXXA
T241	dose 18830 18834	8 mg
T242	tradename 19938 19947	KRYSTEXXA
T243	tradename 20134 20144	KRYSTEXXA.
T244	tradename 20280 20290	KRYSTEXXA.
T245	tradename 22087 22096	KRYSTEXXA
T246	tradename 22259 22268	KRYSTEXXA
T247	tradename 22479 22488	KRYSTEXXA
T248	dose 22489 22493	8 mg
T249	tradename 22509 22518	KRYSTEXXA
T250	dose 22519 22523	8 mg
T251	tradename 22665 22674	KRYSTEXXA
T252	dose 22675 22679	8 mg
T253	tradename 22695 22704	KRYSTEXXA
T254	dose 22705 22709	8 mg
T255	tradename 22906 22916	KRYSTEXXA.
T256	adversereaction 22955 22980	Congestive Heart Failure:
T257	tradename 23096 23105	KRYSTEXXA
T258	dose 23106 23110	8 mg
T259	frequency 23111 23125	every 2 weeks.
T260	tradename 23267 23276	KRYSTEXXA
T261	dose 23277 23281	8 mg
T262	frequency 23282 23295	every 2 weeks
T263	tradename 23514 23523	KRYSTEXXA
T264	dose 23524 23527	8mg
T265	frequency 23528 23541	every 2 weeks
T266	tradename 23644 23653	KRYSTEXXA
T267	tradename 23693 23702	KRYSTEXXA
T268	adversereaction 23729 23739	Gout flare
T269	dose 23741 23745	8 mg
T270	frequency 23746 23759	every 2 weeks
T271	adversereaction 23808 23825	Infusion reaction
T272	adversereaction 23842 23859	Nausea Contusionb
T273	adversereaction 23863 23874	Ecchymosisb
T274	adversereaction 23909 23924	Nasopharyngitis
T275	adversereaction 23939 23951	Constipation
T276	adversereaction 23966 23976	Chest Pain
T277	adversereaction 23991 24002	Anaphylaxis
T278	adversereaction 24017 24025	Vomiting
T279	adversereaction 24312 24321	contusion
T280	adversereaction 24325 24336	ecchymosis,
T281	tradename 24465 24474	KRYSTEXXA
T282	frequency 24475 24489	every 2 weeks,
T283	tradename 24582 24592	KRYSTEXXA.
T284	nanoparticle 24712 24731	pegloticase-induced
T285	adversereaction 24900 24918	infusion reactions
T286	tradename 24996 25005	KRYSTEXXA
T287	frequency 25006 25019	every 2 weeks
T288	nanoparticle 25503 25514	pegloticase
T289	tradename 25637 25646	KRYSTEXXA
T290	surfacecoating 25745 25748	PEG
T291	tradename 26185 26195	KRYSTEXXA.
T292	tradename 26220 26229	KRYSTEXXA
T293	tradename 26397 26406	KRYSTEXXA
T294	nanoparticle 26464 26475	Pegloticase
T295	dose 26517 26538	0, 5, 10, or 40 mg/kg
T296	frequency 26539 26551	twice weekly
T297	routeofadministration 26559 26570	intravenous
T298	dose 26712 26716	8 mg
T299	dose 26718 26729	0.133 mg/kg
T300	frequency 26755 26768	every 2 weeks
T301	tradename 27042 27051	KRYSTEXXA
T302	tradename 27125 27134	KRYSTEXXA
T303	tradename 27274 27283	KRYSTEXXA
T304	dose 27284 27288	8 mg
T305	frequency 27289 27302	every 2 weeks
T306	tradename 27861 27870	KRYSTEXXA
T307	dose 27871 27875	8 mg
T308	frequency 27876 27889	every 2 weeks
T309	tradename 28035 28044	KRYSTEXXA
T310	routeofadministration 28121 28132	intravenous
T311	dose 28141 28146	12 mg
T312	activeingredient 28150 28157	uricase
T313	tradename 28349 28358	KRYSTEXXA
T314	nanoparticle 28360 28372	pegloticase)
T315	activeingredient 28378 28403	uric acid specific enzyme
T316	surfacecoating 28415 28424	PEGylated
T317	activeingredient 28481 28494	urate oxidase
T318	activeingredient 28496 28504	uricase)
T319	activeingredient 28568 28575	Uricase
T320	surfacecoating 28604 28643	monomethoxypoly(ethylene glycol) [mPEG]
T321	molecularweight 28645 28651	10 kDa
T322	molecularweight 28796 28802	34 kDa
T323	nanoparticle 28848 28859	pegloticase
T324	activeingredient 28861 28878	tetrameric enzyme
T325	surfacecoating 28893 28898	mPEG)
T326	molecularweight 28916 28924	540 kDa.
T327	tradename 28926 28935	KRYSTEXXA
T328	routeofadministration 28952 28963	intravenous
T329	tradename 28975 28984	KRYSTEXXA
T330	nanoparticle 29044 29055	pegloticase
T331	tradename 29087 29096	KRYSTEXXA
T332	nanoparticle 29098 29110	pegloticase)
T333	tradename 29189 29198	KRYSTEXXA
T334	dose 29208 29212	8 mg
T335	activeingredient 29216 29223	uricase
T336	molecularweight 29256 29262	10 kDa
T337	surfacecoating 29263 29268	mPEG)
T338	inactiveingredient 29278 29338	Disodium Hydrogen Phosphate Dihydrate (Na2HPO4&#x2022;2H2O),
T339	inactiveingredient 29347 29370	Sodium Chloride (NaCl),
T340	inactiveingredient 29379 29439	Sodium Dihydrogen Phosphate Dihydrate (NaH2PO4&#x2022;2H2O),
T341	inactiveingredient 29444 29449	Water
T342	dose 29475 29479	8 mg
T343	nanoparticle 29483 29494	pegloticase
T344	activeingredient 29499 29506	uricase
T345	tradename 29569 29578	KRYSTEXXA
T346	activeingredient 29584 29609	uric acid specific enzyme
T347	activeingredient 29633 29640	uricase
T348	tradename 29957 29967	KRYSTEXXA,
T349	tradename 30017 30026	KRYSTEXXA
T350	tradename 30057 30066	KRYSTEXXA
T351	dose 30067 30071	8 mg
T352	routeofadministration 30291 30302	intravenous
T353	dose 30316 30340	0.5, 1, 2, 4, 8 or 12 mg
T354	nanoparticle 30344 30355	pegloticase
T355	indication 30376 30392	symptomatic gout
T356	dose 30743 30747	8 mg
T357	dose 30752 30758	12 mg.
T358	nanoparticle 30784 30795	Pegloticase
T359	activeingredient 30853 30860	uricase
T360	routeofadministration 30896 30907	intravenous
T361	dose 30921 30927	0.5 mg
T362	dose 30931 30936	12 mg
T363	nanoparticle 30937 30948	pegloticase
T364	indication 30969 30986	symptomatic gout,
T365	nanoparticle 31019 31030	pegloticase
T366	nanoparticle 31219 31231	pegloticase.
T367	nanoparticle 31423 31434	pegloticase
T368	nanoparticle 31584 31595	pegloticase
T369	routeofadministration 31982 31993	intravenous
T370	tradename 33283 33292	KRYSTEXXA
T371	indication 33328 33340	chronic gout
T372	tradename 33543 33552	KRYSTEXXA
T373	dose 33553 33557	8 mg
T374	frequency 33558 33571	every 2 weeks
T375	frequency 33575 33588	every 4 weeks
T376	tradename 33993 34002	KRYSTEXXA
T377	tradename 34862 34871	KRYSTEXXA
T378	tradename 35141 35150	KRYSTEXXA
T379	frequency 35151 35164	every 2 weeks
T380	frequency 35252 35266	4 week regimen
T381	adversereaction 35376 35387	anaphylaxis
T382	adversereaction 35392 35410	infusion reactions
T383	dose 35753 35757	8 mg
T384	frequency 35758 35771	every 2 weeks
T385	dose 35820 35824	8 mg
T386	frequency 35825 35838	every 4 weeks
T387	dose 35908 35912	8 mg
T388	frequency 35913 35926	every 2 weeks
T389	dose 35974 35978	8 mg
T390	frequency 35979 35992	every 4 weeks
T391	tradename 36284 36293	KRYSTEXXA
T392	tradename 36583 36592	KRYSTEXXA
T393	tradename 37360 37369	KRYSTEXXA
T394	dose 37370 37374	8 mg
T395	frequency 37375 37389	every 2 weeks,
T396	tradename 37390 37399	KRYSTEXXA
T397	dose 37400 37404	8 mg
T398	frequency 37405 37419	every 4 weeks,
T399	tradename 37470 37479	KRYSTEXXA
T400	frequency 37530 37542	every 2 week
T401	frequency 37575 37587	every 4 week
T402	tradename 37656 37665	KRYSTEXXA
T403	routeofadministration 37760 37771	intravenous
T404	tradename 37797 37806	KRYSTEXXA
T405	tradename 37921 37930	KRYSTEXXA
T406	dose 37934 37938	8 mg
T407	tradename 38028 38037	KRYSTEXXA
T408	adversereaction 38531 38542	Anaphylaxis
T409	adversereaction 38547 38565	Infusion Reactions
T410	adversereaction 38576 38587	Anaphylaxis
T411	adversereaction 38592 38610	infusion reactions
T412	adversereaction 38849 38861	anaphylaxis,
T413	adversereaction 38872 38934	wheezing, peri-oral or lingual edema, hemodynamic instability,
T414	adversereaction 38939 38943	rash
T415	adversereaction 38947 38957	urticaria.
T416	adversereaction 39029 39047	infusion reaction,
T417	adversereaction 39058 39067	urticaria
T418	adversereaction 39081 39089	erythema
T419	adversereaction 39113 39120	dyspnea
T420	adversereaction 39145 39184	flushing, chest discomfort, chest pain,
T421	adversereaction 39189 39194	rash.
T422	tradename 39355 39365	KRYSTEXXA.
T423	tradename 39524 39533	KRYSTEXXA
T424	tradename 39590 39600	KRYSTEXXA.
T425	tradename 39687 39696	KRYSTEXXA
T426	tradename 40095 40105	KRYSTEXXA,
T427	tradename 40212 40221	KRYSTEXXA
T428	tradename 40339 40348	KRYSTEXXA
T429	company 40399 40428	Savient Pharmaceuticals, Inc.
